Biogen Inc.

The Food and Drug Administration on Thursday approved the Alzheimer's treatment Leqembi, a pivotal decision that will expand access to the expensive drug for older Americans.Medicare announced shortly after the FDA approval that it is now…

Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)Biogen also reported new real-world evidence and progress on the development of a…

Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for traditional…

A panel of independent advisors to the Food and Drug Administration is meeting Friday to make a recommendation on whether the Alzheimer's drug Leqembi, made by Eisai and Biogen, should receive full approval.The FDA is not required to follow…

Sen. Bernie Sanders (I-VT) arrives to the U.S. Capitol Building on June 01, 2023 in Washington, DC.Anna Moneymaker | Getty ImagesSen. Bernie Sanders on Wednesday called on the U.S. Health and Human Services Department to take action to…

<!-- Name:DistributionId Value:8840117 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | ReutersThe new Alzheimer's antibody treatment Leqembi could cost Medicare up to $5 billion per year, according to research…

The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | via ReutersDemocratic and Republican attorneys general in nearly half of U.S. states are calling on Medicare to provide…

Juanmonino | E+ | Getty ImagesSeniors with early Alzheimer's disease will face major hurdles to get treated even if promising new drugs roll out more broadly in the coming years, putting them at risk of developing more severe disease as…

Chiquita Brooks-LaSure testifies before the Senate Finance Committee during her nomination hearing to be administrator of the Centers for Medicare & Medicaid Services in Washington on Thursday, April 15, 2021.Caroline Brehman | CQ-Roll…